AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8634569 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1785240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (3 mg.kg‐1)
Number of subjects: 105
Study 1785240 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.04 mg.kg‐1)
Number of subjects: 105
Study 1785240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 6341720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous glucose control
Number of subjects: 33
Study 6341720 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 33
Study 6341720 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved blood glucose control
Number of subjects: 33
Study 6341720 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of abnormal nerve function at entry
Number of subjects: 33
Study 31306374 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy combined with bone graft
Number of subjects: 30
Study 31306374 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy alone
Number of subjects: 30
Study 31306374 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy combined with PRF
Number of subjects: 30
Study 31306374 — intervention group
Group type: COMPARATOR
Intervention: Corticotomy-assisted rapid orthodontics
Number of subjects: 30
Study 28144914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including long-term structured physical activity, nutritional counseling/dietary intervention, and an information and communication technology intervention
Number of subjects: 1500
Study 28144914 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging lifestyle education program
Number of subjects: 1500
Study 23438441 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention
Number of subjects: 2038
Study 23438441 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparative schools)
Number of subjects: 2038
Study 22456254 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in the number of pro-drinkers
Number of subjects: 1726
Study 22456254 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in the number of pro-abstainers
Number of subjects: 1726
Study 19150139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (O/A)
Number of subjects: 154
Study 19150139 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine/acetaminophen (C/A)
Number of subjects: 154
Study 19150139 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 154
Study 17517240 — intervention group
Group type: EXPERIMENTAL
Intervention: Central reader interpretations
Number of subjects: 326
Study 17517240 — intervention group
Group type: COMPARATOR
Intervention: Local interpretations
Number of subjects: 326
Study 15968928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 18
Study 15968928 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 18
Study 15968928 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 18
Study 14569512 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of Adriamycin/Cyclophosphamide followed by 4 cycles of Docetaxel
Number of subjects: 0
Study 14569512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response evaluation after 2 cycles of chemotherapy
Number of subjects: 0
Study 10533734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasphincteric injection of botulinum toxin A (20 U injected into each of the four quadrants in the lower esophageal sphincter)
Number of subjects: 24
Study 10533734 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilation
Number of subjects: 24
Study 8923549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopean objects (C)
Number of subjects: 0
Study 8923549 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocularly visible objects (M)
Number of subjects: 0
Study 8923549 — intervention group
Group type: COMPARATOR
Intervention: Cyclopean inducers (C)
Number of subjects: 0
Study 8923549 — intervention group
Group type: COMPARATOR
Intervention: Monocular inducers (M)
Number of subjects: 0
Study 1824760 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 11
Study 1824760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 11
Study 1824760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6874173 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of potassium‐magnesium aspartate over a 24‐h period
Number of subjects: 8
Study 6874173 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study 6874173 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of potassium‐magnesium aspartate
Number of subjects: 8
Study 29985223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexagonal Bar (HEX)
Number of subjects: 29
Study 29985223 — intervention group
Group type: COMPARATOR
Intervention: Barbell (BAR)
Number of subjects: 29
Study 30764778 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of diagnosed chronic conditions
Number of subjects: 43501
Study 30764778 — intervention group
Group type: EXPERIMENTAL
Intervention: Final parsimonious model including age, sex, and concession card status
Number of subjects: 43501
Study 30764778 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 43501
Study 30764778 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonwealth Concessional Health Care Card holders
Number of subjects: 43501
Study 30764778 — intervention group
Group type: EXPERIMENTAL
Intervention: Each chronic condition
Number of subjects: 43501
Study 30764778 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 43501
Study 30012909 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-level Retrolaminar Paravertebral Block (RLB) with 15 ml ropivacaine (0.5%) for each lamina of T2 and T4 vertebrae
Number of subjects: 122
Study 30012909 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same volume of normal saline at each level
Number of subjects: 122
Study 26910598 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (n=26)
Number of subjects: 50
Study 26910598 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP, n=24)
Number of subjects: 50
Study 25215617 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive game-based training platforms
Number of subjects: 60
Study 25215617 — intervention group
Group type: COMPARATOR
Intervention: Conventional task-based training
Number of subjects: 60
Study 23072517 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity plus fatigue management intervention
Number of subjects: 189
Study 23072517 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity-only intervention
Number of subjects: 189
Study 23072517 — intervention group
Group type: COMPARATOR
Intervention: Contact-control social support intervention
Number of subjects: 189
Study 20109087 — intervention group
Group type: EXPERIMENTAL
Intervention: NAL-NL1
Number of subjects: 48
Study 20109087 — intervention group
Group type: COMPARATOR
Intervention: DSL v.4.1
Number of subjects: 48
Study 20109087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligibility judgments
Number of subjects: 48
Study 20109087 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for NAL
Number of subjects: 48
Study 17592920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium added to antidepressants (tricyclics and tetracyclics) for acceleration
Number of subjects: 500
Study 17592920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium added to various antidepressants (including SSRIs) for augmentation
Number of subjects: 500
Study 16234140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training in pelvic floor exercises
Number of subjects: 234
Study 16234140 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 234
Study 11897760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (100 to 400 ng/min)
Number of subjects: 32
Study 11897760 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (3.2 to 12.8 microg/min)
Number of subjects: 32
Study 11897760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (1.6 to 6.4 microg/min)
Number of subjects: 32
Study 11897760 — intervention group
Group type: COMPARATOR
Intervention: Bradykinin
Number of subjects: 32
Study 10734331 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 60
Study 10734331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7572010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 micrograms kg‐1 min‐1)
Number of subjects: 40
Study 7572010 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (0.5 or 2.5 micrograms kg‐1 min‐1)
Number of subjects: 40
Study 7572010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2140122 — intervention group
Group type: EXPERIMENTAL
Intervention: E1,MP‐‐E2,MP
Number of subjects: 20
Study 2140122 — intervention group
Group type: EXPERIMENTAL
Intervention: E1,EMRR‐‐E2,EMRR
Number of subjects: 20
Study 2140122 — intervention group
Group type: EXPERIMENTAL
Intervention: E1,MP‐‐E2,EMRR
Number of subjects: 20
Study 2140122 — intervention group
Group type: EXPERIMENTAL
Intervention: E2,MP‐‐E1,EMRR
Number of subjects: 20
Study 2140122 — intervention group
Group type: EXPERIMENTAL
Intervention: E1,MP‐‐E1,EMRR
Number of subjects: 20
Study 2140122 — intervention group
Group type: EXPERIMENTAL
Intervention: E2,MP‐‐E2,EMRR
Number of subjects: 20
Study 633779 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g cephradine with 40 mg furosemide t.i.d. peroral
Number of subjects: 11
Study 633779 — intervention group
Group type: COMPARATOR
Intervention: 4 g cephalothin
Number of subjects: 11
Study 30552239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mana Tū programme
Number of subjects: 400
Study 30552239 — intervention group
Group type: COMPARATOR
Intervention: Wait list for the programme
Number of subjects: 400
Study 27593879 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrust plus MI‐E
Number of subjects: 40
Study 27593879 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐E
Number of subjects: 40
Study 27593879 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual assistance following MIC maneuver
Number of subjects: 40
Study 27593879 — intervention group
Group type: COMPARATOR
Intervention: Unassisted cough
Number of subjects: 40
Study 24709995 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous upper-limb movements with mirror visual feedback
Number of subjects: 35
Study 24709995 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous upper-limb movements without mirror visual feedback
Number of subjects: 35
Study 24709995 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous upper-limb movements with mirror visual feedback
Number of subjects: 35
Study 24709995 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous upper-limb movements without mirror visual feedback
Number of subjects: 35
Study 24709995 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 35
Study 24429861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusafungine (Bioparox)
Number of subjects: 61
Study 20804454 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen etemesil 1200 mg twice daily (n = 61)
Number of subjects: 120
Study 20804454 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily (n = 59)
Number of subjects: 120
Study 20804454 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen etemesil
Number of subjects: 120
Study 20804454 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 120
Study 18439501 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter uterine artery embolization (UAE)
Number of subjects: 16
Study 18439501 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter uterine artery occlusion (UAO)
Number of subjects: 16
Study 18439501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both UAE and UAO
Number of subjects: 16
Study 16419643 — intervention group
Group type: EXPERIMENTAL
Intervention: 46 mg GCE once a day
Number of subjects: 117
Study 16419643 — intervention group
Group type: EXPERIMENTAL
Intervention: 93 mg GCE once a day
Number of subjects: 117
Study 16419643 — intervention group
Group type: EXPERIMENTAL
Intervention: 185 mg GCE once a day
Number of subjects: 117
Study 16419643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 12640589 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine at a mean dose of 24.9 mg/d (range 12.5-37.2 mg/d)
Number of subjects: 7
Study 12640589 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine at a mean dose of 24.9 mg/d
Number of subjects: 7
Study 10476745 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline)
Number of subjects: 116
Study 10476745 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 116
Study 8877666 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sanguinarine (Sa)
Number of subjects: 201
Study 8877666 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 201
Study 8877666 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 201
Study 8877666 — intervention group
Group type: COMPARATOR
Intervention: Supragingival plaque control (SPC)
Number of subjects: 201
Study 1706282 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg of octreotide acetate subcutaneously before pancreatography
Number of subjects: 63
Study 1706282 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium-chloride
Number of subjects: 63
Study 6418972 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 40% above anaerobic threshold
Number of subjects: 29
Study 6418972 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at anaerobic threshold
Number of subjects: 29
Study 6418972 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 40% below anaerobic threshold
Number of subjects: 29
Study 30873657 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide therapy for 6 months
Number of subjects: 24
Study 30873657 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal phase (control)
Number of subjects: 24
Study 29307004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' decision
Number of subjects: 247
Study 29307004 — intervention group
Group type: COMPARATOR
Intervention: Leeds criteria
Number of subjects: 247
Study 29307004 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement in P. aeruginosa status among adults providing sputum samples
Number of subjects: 247
Study 29307004 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement in P. aeruginosa status among adults > 25 years old
Number of subjects: 247
Study 25753551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (vitamin D3)
Number of subjects: 191
Study 25753551 — intervention group
Group type: COMPARATOR
Intervention: Control (culture-negative household contacts)
Number of subjects: 191
Study 25753551 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR‐TB
Number of subjects: 191
Study 25520340 — intervention group
Group type: EXPERIMENTAL
Intervention: SR71 stem (carbon-fiber-composite)
Number of subjects: 60
Study 25520340 — intervention group
Group type: COMPARATOR
Intervention: Stability stem (all-metal)
Number of subjects: 60
Study 25520340 — intervention group
Group type: EXPERIMENTAL
Intervention: SR71 stem
Number of subjects: 60
Study 25520340 — intervention group
Group type: COMPARATOR
Intervention: Stability stem
Number of subjects: 60
Study 22450386 — intervention group
Group type: EXPERIMENTAL
Intervention: hT(2)W‐3D‐FLAIR obtained 10 min, 3.5 hours, and 4 hours after GBCM administration in Group A
Number of subjects: 10
Study 22450386 — intervention group
Group type: COMPARATOR
Intervention: hT(2)W‐3D‐FLAIR obtained before and 10 min, 4 hours, and 4.5 hours after GBCM administration in Group B
Number of subjects: 10
Study 22450386 — intervention group
Group type: EXPERIMENTAL
Intervention: Grades of EH evaluated at 3.5 and 4 hours in Group A
Number of subjects: 10
Study 22450386 — intervention group
Group type: COMPARATOR
Intervention: Grades of EH evaluated at 4 and 4.5 hours in Group B
Number of subjects: 10
Study 20533449 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine care
Number of subjects: 10
Study 20533449 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study 18797646 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention and contact (BIC) plus treatment as usual
Number of subjects: 1867
Study 18797646 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1867
Study 15916253 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 61
Study 15916253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-specific relapse prevention counseling module
Number of subjects: 61
Study 15916253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 61
Study 12919182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus with corticosteroids (prednisone)
Number of subjects: 65
Study 12919182 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus with daclizumab
Number of subjects: 65
Study 12919182 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid group (prednisone)
Number of subjects: 65
Study 11262469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered iron sucrose plus recombinant human erythropoietin
Number of subjects: 40
Study 11262469 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered iron sucrose alone
Number of subjects: 40
Study 9429991 — intervention group
Group type: EXPERIMENTAL
Intervention: High percentage of calories from fat feedback
Number of subjects: 0
Study 9429991 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate percentage of calories from fat feedback
Number of subjects: 0
Study 9429991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low percentage of calories from fat feedback
Number of subjects: 0
Study 9429991 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomly assigned risk factor feedback
Number of subjects: 0
Study 8509693 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation
Number of subjects: 20
Study 8509693 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 3443154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 0.5 mg
Number of subjects: 20
Study 3443154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 1.25 mg
Number of subjects: 20
Study 3443154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg
Number of subjects: 20
Study 3443154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 5 mg
Number of subjects: 20
Study 3443154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31743554 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP 3%
Number of subjects: 0
Study 31743554 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP 1%
Number of subjects: 0
Study 31743554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31261570 — intervention group
Group type: EXPERIMENTAL
Intervention: YIC therapeutic vaccine
Number of subjects: 53
Study 29160559 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction and positive reinforcement
Number of subjects: 37
Study 29160559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 37
Study 25126854 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 with polysorbate 80 (P80)
Number of subjects: 0
Study 25126854 — intervention group
Group type: COMPARATOR
Intervention: PCV13 without polysorbate 80 (P80)
Number of subjects: 0
Study 23602291 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose IV omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 88
Study 21553972 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity advice delivered by professional staff
Number of subjects: 181
Study 21553972 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity advice delivered by trained volunteer peers
Number of subjects: 181
Study 21553972 — intervention group
Group type: COMPARATOR
Intervention: Attention-control arm of staff-delivered telephone support for nutrition
Number of subjects: 181
Study 19008718 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg for 3 months
Number of subjects: 18
Study 19008718 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg for 3 months
Number of subjects: 18
Study 16840396 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy and respiratory exercises
Number of subjects: 24
Study 16840396 — intervention group
Group type: COMPARATOR
Intervention: Control group (respiratory exercise only)
Number of subjects: 24
Study 12919430 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Muscle Tension (AMT)
Number of subjects: 605
Study 12919430 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 605
Study 12919430 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 605
Study 11081989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (100 mg 2-3 times/day for 2 months)
Number of subjects: 40
Study 11081989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9322471 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus of clonidine 150 micrograms plus morphine 2 mg
Number of subjects: 68
Study 9322471 — intervention group
Group type: COMPARATOR
Intervention: Epidural patient-controlled analgesia (PCEA) with bupivacaine 0.25% and sufentanil 2 micrograms/mL
Number of subjects: 68
Study 8139175 — intervention group
Group type: EXPERIMENTAL
Intervention: Enduracin (long-acting nicotinic acid)
Number of subjects: 31
Study 30856182 — intervention group
Group type: EXPERIMENTAL
Intervention: siPRBCs (stored for 33±4 days)
Number of subjects: 19
Study 30856182 — intervention group
Group type: COMPARATOR
Intervention: fPRBCs (stored for 10±3 days)
Number of subjects: 19